Chapter Two - The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
Introduction
After decades of controversy, the ability of the immune system to influence cancer development and progression has now become apparent (Grivennikov et al., 2010, Mantovani et al., 2008, Schreiber et al., 2011, Shankaran et al., 2001). Two parallel lines of investigation, one focused on assessing naturally occurring immune responses to developing cancers and the other focused on immunotherapy-induced durable responses to established tumors have ultimately led to unequivocal resolution of this long-standing argument. These independent approaches have demonstrated the importance of tumor-specific neoantigens as critical targets of antitumor immune responses (Schumacher & Schreiber, 2015). Immune recognition of neoantigens has the potential to destroy developing cancers before they become clinically apparent, shape the immunogenicities of cancer cells rendering them more fit to grow progressively in an immunocompetent environment, and ultimately to facilitate the immune elimination of growing tumors when manipulated in the appropriate therapeutic manner. The concept that neoantigens may be optimal targets for cancer immunotherapy is a very old one dating back to the 1940s and steadily evolving since that time (Table 1). The evolution of this idea has undergone a dramatic acceleration with the advent and employment of next generation sequencing and computational approaches which have made it possible to predict cancer specific mutations that function as neoantigens for adaptive immunity (Gubin, Artyomov, Mardis, & Schreiber, 2015). The analyses of therapeutically active neoantigens has also led to the realization that both major histocompatibility complex (MHC) class I (MHC I) and MHC class II (MHC II) epitopes are required for effective antitumor immune responses. These developments now leave cancer immunologists and clinical oncologists poised to develop truly personalized treatment approaches against established cancers with the goal of increasing specificity and eliminating toxicity compared to the current therapies. The focus of this review is to summarize the key experimental evidence that has led to a paradigm shift in thinking about immune system–cancer interactions resulting in the current excitement over using neoantigens as tumor-specific targets for immune control of cancer.
Section snippets
Cancer Immunoediting as an Encompassing Model of Immune System–Tumor Interactions
The dual host-protective and tumor-promoting actions of the immune system on developing cancers have been codified as a process termed “Cancer Immunoediting” (Fig. 1; Schreiber et al., 2011, Shankaran et al., 2001). Cancer Immunoediting initiates after cellular transformation has occurred and intrinsic tumor suppressor mechanisms have been circumvented. In its most complex form, Cancer Immunoediting is comprised of three phases: Elimination, Equilibrium, and Escape. In the Elimination phase,
Antigenic Targets of Cancer Immunoediting
A central tenet of Cancer Immunoediting is that recognition of tumor antigens by T cells drives the immunological sculpting of cancers. Tumor antigens can be divided into three broad categories: (a) tumor-associated antigens (TAA), (b) cancer-germline/cancer testis antigens (CTA), and (c) tumor-specific antigens (TSAs) (Coulie et al., 2014, Heemskerk et al., 2013).
TAA are comprised of proteins encoded by genes encoded in the normal genome that may represent either normal differentiation
Setting the Groundwork: Genomic Approaches to Cancer Antigen Identification
Advances in next generation sequencing allowed for whole genome sequencing of cancers and a better understanding of the mutational landscape present in many cancers (Koboldt, Steinberg, Larson, Wilson, & Mardis, 2013). In 2008, James Allison and Bert Vogelstein performed in silico analysis combining breast and colorectal cancer-sequencing data with epitope prediction algorithms and hypothesized that breast and colorectal cancers accumulate unique HLA epitopes (Segal et al., 2008). They proposed
Developing Cancer Immunotherapies Based on Genomic Identification of Tumor-Specific Neoantigens
Using neoantigens for therapeutic benefit has significant conceptual advantages over the use of TAA. The former are expressed exclusively by transformed cells and therefore are similar to foreign proteins in that they are not subject to central immunological tolerance. Perhaps equally important, neoantigens are tumor specific and therefore targeting them obviates concerns about cytotoxicity toward healthy tissue. Indeed, accumulating data suggest that neoantigens are important components of
Neoantigens as Therapeutic Targets in Human Cancer
As our understanding of the dual functions of the immune system to both eliminate and sculpt the development of progressively growing tumors evolved, so too did the capacity to use the immune system as a therapeutic tool to control cancer. The recognition that tumor antigens were key to the immune system's capacity to discriminate between cancer cells and normal self formed the basis for many early clinical vaccine trials targeting TAA and subsequently CTA as antigens. While occasional
Concluding Remarks
Two parallel lines of investigation, one focused on the identification of endogenous immune responses to cancer, and the other on defining antigens that serve as therapeutically useful targets for immunotherapies, have both led to the same conclusion that tumor-specific neoantigens are ideal targets for immunotherapy. Where does the field go from here? The currently available bioinformatics approaches to identify neoantigens are clearly successful, but it is now apparent that the majority of in
Acknowledgments
We are grateful to T. Noguchi for constructive criticism and comments. R.D.S. receives research support from the National Cancer Institute (RO1 CA043059, RO1 CA190700, U01 CA141541), the Cancer Research Institute, the WWWW Foundation, the Siteman Cancer Center/Barnes-Jewish Hospital (Cancer Frontier Fund), Bristol-Myers Squibb Inc., Janssen and Stand Up to Cancer. J.P.W. is supported by a T32 training grant in hematology (5T32HL007088-40) from the National Heart, Lung, and Blood Institute.
References (174)
- et al.
Oncology meets immunology: The cancer-immunity cycle
Immunity
(2013) - et al.
Structure, chromosomal location, and expression pattern of three mouse genes homologous to the human MAGE genes
Genomics
(1995) - et al.
Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies
Molecular Immunology
(2015) - et al.
The immunobiology of cancer immunosurveillance and immunoediting
Immunity
(2004) - et al.
MHC-NP: Predicting peptides naturally processed by the MHC
Journal of Immunological Methods
(2013) - et al.
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
Lancet
(1995) - et al.
Immunity, inflammation, and cancer
Cell
(2010) - et al.
Hallmarks of cancer: The next generation
Cell
(2011) - et al.
Natural cell-mediated immunity
Advances in Cancer Research
(1978) T-cell function and specificity in athymic mice
Immunology Today
(1983)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Blood
The next-generation sequencing revolution and its impact on genomics
Cell
Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4 + T cells
Journal of Molecular Biology
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Blood
New insights into cancer immunoediting and its three component phases—Elimination, equilibrium and escape
Current Opinion in Immunology
Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry
Nature Protocols
Signatures of mutational processes in human cancer
Nature
Phenotypic analysis of antigen-specific T lymphocytes
Science
Binding of immunogenic peptides to Ia histocompatibility molecules
Nature
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
Journal of Experimental Medicine
Restoring function in exhausted CD8 T cells during chronic viral infection
Nature
Cancer risk after renal transplantation in the Nordic countries, 1964–1986
International Journal of Cancer
Structure of the human class I histocompatibility antigen, HLA-A2
Nature
Pathways of antigen processing
Annual Review of Immunology
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
The New England Journal of Medicine
T-helper-1-cell cytokines drive cancer into senescence
Nature
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Genome Research
Cancer: A biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications
British Medical Journal
The concept of immunological surveillance
Progress in Experimental Tumor Research
Properties of MHC class I presented peptides that enhance immunogenicity
PLoS Computational Biology
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
Science Translational Medicine
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Science
Exploiting the mutanome for tumor vaccination
Cancer Research
Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans
Clinical Cancer Research
TIGIT and PD-1 impair tumor antigen-specific CD8 + T cells in melanoma patients
The Journal of Clinical Investigation
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Proceedings of the National Academy of Sciences of the United States of America
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia
Science Translational Medicine
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
Proceedings of the National Academy of Sciences of the United States of America
Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy
Nature Reviews. Cancer
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
Science
Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of tum- antigen P91A and identification of the tum- mutation
Proceedings of the National Academy of Sciences of the United States of America
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
The Journal of Experimental Medicine
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Nature
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine
Targeting of HPV-16 + epithelial cancer cells by TCR gene engineered T cells directed against E6
Clinical Cancer Research
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68
The Journal of Experimental Medicine
Cancer immunoediting: From immunosurveillance to tumor escape
Nature Immunology
The three Es of cancer immunoediting
Annual Review of Immunology
Expression of tumour-specific antigens underlies cancer immunoediting
Nature
Cited by (168)
Are we getting closer to a successful neoantigen cancer vaccine?
2024, Molecular Aspects of MedicineProduction of monoclonal antibodies for therapeutic purposes: A review
2023, International ImmunopharmacologyMetastasis prevention: How to catch metastatic seeds
2023, Biochimica et Biophysica Acta - Reviews on CancerAnalysis of tumor-immune functional responses in a mathematical model of neoantigen cancer vaccines
2023, Mathematical Biosciences
- 1
These authors contributed equally to this work.